Journal for ImmunoTherapy of Cancer: 9 (10)

Basic tumor immunology

Original research: Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis (29 October, 2021)
Chenghui Yang, Zhen Wang, Lili Li, Zhigang Zhang, Xiaoyan Jin, Pin Wu, Shanshan Sun, Jun Pan, Ke Su, Fang Jia, Leyi Zhang, Haijun Wang, Xiuyan Yu, Xuan Shao, Ke Wang, Fuming Qiu, Jun Yan, Jian Huang
Original research: Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy (29 October, 2021)
Kim E Kortekaas, Saskia J Santegoets, Liselotte Tas, Ilina Ehsan, Pornpimol Charoentong, Helena C van Doorn, Mariette I E van Poelgeest, Dana A M Mustafa, Sjoerd H van der Burg
Original research: PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy (25 October, 2021)
Yiqi Xu, Zhenyue Gao, Ruxin Hu, Yuqing Wang, Yuhong Wang, Zheng Su, Xiaoyue Zhang, Jingxuan Yang, Mei Mei, Yu Ren, Min Li, Xuan Zhou
Original research: Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth (25 October, 2021)
Anne Marijne Heeren, Jossie Rotman, Sanne Samuels, Henry J M A A Zijlmans, Guus Fons, Koen K van de Vijver, Maaike C G Bleeker, Gemma G Kenter, Ekaterina J Jordanova, Tanja D de Gruijl
Original research: Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome (18 October, 2021)
Carlo Sorrentino, Stefania Livia Ciummo, Luigi D'Antonio, Cristiano Fieni, Paola Lanuti, Alice Turdo, Matilde Todaro, Emma Di Carlo
Original research:
Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma
(13 October, 2021)
Yuwei Deng, Wenjia Su, Junwen Zhu, Hongfei Ji, Xiaoping Zhou, Jingshu Geng, Jiayu Zhu, Qingyuan Zhang
Original research: Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice (12 October, 2021)
Cangang Zhang, Lei Lei, Xiaofeng Yang, Kaili Ma, Huiqiang Zheng, Yanhong Su, Anjun Jiao, Xin Wang, Haiyan Liu, Yujing Zou, Lin Shi, Xiaobo Zhou, Chenming Sun, Yuzhu Hou, Zhengtao Xiao, Lianjun Zhang, Baojun Zhang
Original research: Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy (11 October, 2021)
Briana Rose Halle, Allison Betof Warner, Farzana Y Zaman, Andrew Haydon, Prachi Bhave, Anna K Dewan, Fei Ye, Rebecca Irlmeier, Paras Mehta, Nicholas R Kurtansky, Mario E Lacouture, Jessica C Hassel, Jacob S Choi, Jeffrey A Sosman, Sunandana Chandra, Tracey S Otto, Ryan Sullivan, Meghan J Mooradian, Steven T Chen, Florentia Dimitriou, Georgina Long, Matteo Carlino, Alexander Menzies, Douglas B Johnson, Veronica M Rotemberg
Original research: Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma (8 October, 2021)
Peipei Wang, Yueyun Chen, Qingqin Long, Qing Li, Jiangfang Tian, Ting Liu, Yong Wu, Zhenyu Ding
Original research: Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy (6 October, 2021)
Pascale Lejeune, Véronique Cruciani, Axel Berg-Larsen, Andreas Schlicker, Anne Mobergslien, Lisa Bartnitzky, Sandra Berndt, Sabine Zitzmann-Kolbe, Claudia Kamfenkel, Stefan Stargard, Stefanie Hammer, Jennifer S Jørgensen, Malene Jackerott, Carsten H Nielsen, Christoph A Schatz, Hartwig Hennekes, Jenny Karlsson, Alan S Cuthbertson, Dominik Mumberg, Urs B Hagemann
Original research:
Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
(4 October, 2021)
Hee Sang Hwang, Deokhoon Kim, Jene Choi
Original research: Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer (1 October, 2021)
Huicheng Liu, Lili Bai, Liu Huang, Na Ning, Lin Li, Yijia Li, Xuejiao Dong, Qiuyang Du, Minghui Xia, Yufei Chen, Likun Zhao, Yanhu Li, Qingwu Meng, Jing Wang, Yaqi Duan, Jie Ming, Andy Qingan Yuan, Xiang-Ping Yang
Original research: Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors (1 October, 2021)
Ana Marcu, Andreas Schlosser, Anne Keupp, Nico Trautwein, Pascal Johann, Matthias Wölfl, Johanna Lager, Camelia Maria Monoranu, Juliane S Walz, Lisa M Henkel, Jürgen Krauß, Martin Ebinger, Martin Schuhmann, Ulrich Wilhelm Thomale, Torsten Pietsch, Erdwine Klinker, Paul G Schlegel, Florian Oyen, Yair Reisner, Hans-Georg Rammensee, Matthias Eyrich
Original research: Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies (1 October, 2021)
Amy A Lo, Andrew Wallace, Daniel Oreper, Nicolas Lounsbury, Charles Havnar, Ximo Pechuan-Jorge, Thomas D Wu, Richard Bourgon, Ryan Jones, Katrina Krogh, Guang-Yu Yang, Oliver A Zill
Original research: Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment (1 October, 2021)
Wan-Lun Yan, Chiao-Chieh Wu, Kuan-Yin Shen, Shih-Jen Liu

Case report

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission (29 October, 2021)
Tejus Satish, Shaheer Khan, Matt Levin, Richard Carvajal, Angela J Yoon
Nivolumab-associated DRESS in a genetic susceptible individual (1 October, 2021)
Luoyan Ai, Jie Gao, Shihai Zhao, Qian Li, Yue-Hong Cui, Qing Liu, Duojiao Wu, Yimei Wang, Xiaoshi Jin, Yuan Ji, Jingjie Li, Yiyi Yu, Tianshu Liu

Clinical/translational cancer immunotherapy

Original research: Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma (29 October, 2021)
Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Maaike Nederend, Marco Jansen, Chilam Chan, Kevin Budding, Stefan Nierkens, Thomas Valerius, Friederike Meyer-Wentrup, Niels Eijkelkamp, Jeanette Leusen
Original research: JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (28 October, 2021)
Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto
Original research:
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
(28 October, 2021)
Kjersti Flatmark, Annette Torgunrud, Karianne G Fleten, Ben Davidson, Hedvig V Juul, Nadia Mensali, Christin Lund-Andersen, Else Marit Inderberg
Original research: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab (26 October, 2021)
Paul B Chapman, Vetri Sudar Jayaprakasam, Katherine S Panageas, Margaret Callahan, Michael A Postow, Alexander N Shoushtari, Jedd D Wolchok, Allison Betof Warner
Original research: High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer (20 October, 2021)
Hyung Soon Park, Yoo Min Kim, Sewha Kim, Won Suk Lee, So Jung Kong, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Su-Jin Shin, Chan Kim, Hong Jae Chon
Original research: Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial (18 October, 2021)
Joël Guigay, Keun-Wook Lee, Manish R Patel, Amaury Daste, Deborah J Wong, Sanjay Goel, Michael S Gordon, Martin Gutierrez, Ani Balmanoukian, Christophe Le Tourneau, Alain Mita, Damien Vansteene, Ulrich Keilholz, Patrick Schöffski, Hans Juergen Grote, Dongli Zhou, Marcis Bajars, Nicolas Penel
Original research: Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment (18 October, 2021)
Sumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, Shalini S Yadav, Sreyashi Basu, Hong Chen, Sonali Jindal, Rebecca S S Tidwell, Ashwin Varma, Christopher J Logothetis, James P Allison, Paul G Corn, Padmanee Sharma
Original research: Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES) (8 October, 2021)
Peter Kar Han Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J Young, Amir Iravani, Hanxian Aw Yeang, Ismael A Vergara, David Kok, Kate Drummond, Paul Joseph Neeson, Karen E Sheppard, Tony Papenfuss, Benjamin J Solomon, Shahneen Sandhu, Grant A McArthur
Original research: Acute kidney injury in patients treated with immune checkpoint inhibitors (8 October, 2021)
Shruti Gupta, Samuel A P Short, Meghan E Sise, Jason M Prosek, Sethu M Madhavan, Maria Jose Soler, Marlies Ostermann, Sandra M Herrmann, Ala Abudayyeh, Shuchi Anand, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Wei-Ting Chang, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Abhijat Kitchlu, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Mark Eijgelsheim, Harish Seethapathy, Meghan D Lee, Ian A Strohbehn, Dwight H. Owen, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Lucy Flanders, Busra Isik, Omar Mamlouk, Jamie S Lin, Pablo Garcia, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Els Wauters, Sunandana Chandra, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Suraj Sarvode Mothi, Harkarandeep Singh, Deborah Schrag, Kenar D Jhaveri, Kerry L Reynolds, Frank B Cortazar, David E Leaf
Original research:
CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
(4 October, 2021)
Ravikumar Muthuswamy, AJ Robert McGray, Sebastiano Battaglia, Wenjun He, Anthony Miliotto, Cheryl Eppolito, Junko Matsuzaki, Tsuji Takemasa, Richard Koya, Thinle Chodon, Brian D Lichty, Protul Shrikant, Kunle Odunsi
Original research: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach (4 October, 2021)
Samuel Peter Heilbroner, Reed Few, Tomas G Neilan, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus
Original research: Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects (4 October, 2021)
Meggy Suarez-Carmona, Anja Williams, Jutta Schreiber, Nicolas Hohmann, Ulrike Pruefer, Jürgen Krauss, Dirk Jäger, Anna Frömming, Diana Beyer, Dirk Eulberg, Jarf Ulf Jungelius, Matthias Baumann, Aram Mangasarian, Niels Halama
Original research: Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study (1 October, 2021)
Marc Oliva, Douglas Chepeha, Daniel V Araujo, J. Javier Diaz-Mejia, Peter Olson, Amy Prawira, Anna Spreafico, Scott V Bratman, Tina Shek, John de Almeida, Aaron R Hansen, Andrew Hope, David Goldstein, Ilan Weinreb, Stephen Smith, Bayardo Perez-Ordoñez, Jonathan Irish, Dax Torti, Jeffrey P. Bruce, Ben X. Wang, Anthony Fortuna, Trevor J. Pugh, Hirak Der-Torossian, Ronald Shazer, Nickolas Attanasio, Qingyan Au, Antony Tin, Jordan Feeney, Himanshu Sethi, Alexey Aleshin, Isan Chen, Lillian Siu
Original research: Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity (1 October, 2021)
Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Sheng Ding, Wenjing Yang, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers, Shahram Salek-Ardakani
Original research: Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence (1 October, 2021)
Craig L Slingluff, Karl D Lewis, Robert Andtbacka, John Hyngstrom, Mohammed Milhem, Svetomir N Markovic, Tawnya Bowles, Omid Hamid, Leonel Hernandez-Aya, Joel Claveau, Sekwon Jang, Prejesh Philips, Shernan G Holtan, Montaser F Shaheen, Brendan Curti, William Schmidt, Marcus O Butler, Juan Paramo, Jose Lutzky, Arvinda Padmanabhan, Sajeve Thomas, Daniel Milton, Andrew Pecora, Takami Sato, Eddy Hsueh, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Robert Weber, Edward Levine, Adam Berger, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Brian Gastman, Peter Beitsch, Suthee Rapisuwon, John Glaspy, Edward C McCarron, Vinay Gupta, Deepti Behl, Brent Blumenstein, Joanna J Peterkin

Immunotherapy biomarkers

Original research: Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer (27 October, 2021)
Patricia Rich, R Brian Mitchell, Eric Schaefer, Paul R Walker, John W Dubay, Jason Boyd, David Oubre, Ray Page, Mazen Khalil, Suman Sinha, Scott Boniol, Hafez Halawani, Edgardo S Santos, Warren Brenner, James M Orsini, Emily Pauli, Jonathan Goldberg, Andrea Veatch, Mitchell Haut, Bassam Ghabach, Savita Bidyasar, Maria Quejada, Waseemullah Khan, Kan Huang, Linda Traylor, Wallace Akerley
Original research:
⁶⁸Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
(22 October, 2021)
Sarah Boughdad, Sofiya Latifyan, Craig Fenwick, Hasna Bouchaab, Madeleine Suffiotti, Javid J Moslehi, Joe-Elie Salem, Niklaus Schaefer, Marie Nicod-Lalonde, Julien Costes, Matthieu Perreau, Olivier Michielin, Solange Peters, John O Prior, Michel Obeid
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases (20 October, 2021)
Benjamin Y Lu, Richa Gupta, Adam Aguirre-Ducler, Nicole Gianino, Hailey Wyatt, Matthew Ribeiro, Veronica L Chiang, Joseph N Contessa, Adebowale J Adeniran, Lucia B Jilaveanu, Harriet M Kluger, Kurt A Schalper, Sarah B Goldberg
Original research: MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas (19 October, 2021)
Qiang-Wei Wang, Li-Hua Sun, Ying Zhang, Zheng Wang, Zheng Zhao, Zhi-Liang Wang, Kuan-Yu Wang, Guan-Zhang Li, Jian-Bao Xu, Chang-Yuan Ren, Wen-Ping Ma, Hong-Jun Wang, Shou-Wei Li, Yong-Jian Zhu, Tao Jiang, Zhao-Shi Bao
Original research: PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine (7 October, 2021)
Elisa Baldelli, K Alex Hodge, Guido Bellezza, Neil J Shah, Guido Gambara, Angelo Sidoni, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Lance Liotta, Johann de Bono, Niven Mehra, Ruth Riisnaes, Antonella Ravaggi, Franco Odicino, Maria Isabella Sereni, Matthew Blackburn, Angela Zupa, Giuseppina Improta, Perry Demsko, Lucio Crino', Vienna Ludovini, Giuseppe Giaccone, Emanuel F Petricoin, Mariaelena Pierobon
Original research: Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab (7 October, 2021)
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D Curti, Walter J Urba, Brian D Piening, William L Redmond
Original research: Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer (6 October, 2021)
Yi-Fan Zhou, Yi Xiao, Xi Jin, Gen-Hong Di, Yi-Zhou Jiang, Zhi-Ming Shao
Original research: PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma (1 October, 2021)
Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, Neil J. Shah, David Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refaie, Suthee Rapisuwon, Michael B. Atkins

Immune cell therapies and immune cell engineering

Original research: 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells (27 October, 2021)
Emiliano Roselli, Justin C Boucher, Gongbo Li, Hiroshi Kotani, Kristen Spitler, Kayla Reid, Estelle V Cervantes, Yannick Bulliard, Nhan Tu, Sae Bom Lee, Bin Yu, Frederick L Locke, Marco L Davila
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study (26 October, 2021)
Carla S Walti, Andrea N Loes, Kiel Shuey, Elizabeth M Krantz, Jim Boonyaratanakornkit, Jacob Keane-Candib, Tillie Loeffelholz, Caitlin R Wolf, Justin J Taylor, Rebecca A Gardner, Damian J Green, Andrew J Cowan, David G Maloney, Cameron J Turtle, Steven A Pergam, Helen Y Chu, Jesse D Bloom, Joshua A Hill
Original research: Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors (18 October, 2021)
Chia-Ing Jan, Shi-Wei Huang, Peter Canoll, Jeffrey N Bruce, Yu-Chuan Lin, Chih-Ming Pan, Hsin-Man Lu, Shao-Chih Chiu, Der-Yang Cho
Original research: Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy (6 October, 2021)
Marie Tourret, Nana Talvard-Balland, Marion Lambert, Ghada Ben Youssef, Mathieu F Chevalier, Armelle Bohineust, Thomas Yvorra, Florence Morin, Saba Azarnoush, Olivier Lantz, Jean-Hugues Dalle, Sophie Caillat-Zucman
Original research: Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy (6 October, 2021)
Huan He, Qibin Liao, Chen Zhao, Cuisong Zhu, Meiqi Feng, Zhuoqun Liu, Lang Jiang, Linxia Zhang, Xiangqing Ding, Min Yuan, Xiaoyan Zhang, Jianqing Xu
Original research: Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types (4 October, 2021)
Anders Handrup Kverneland, Christopher Aled Chamberlain, Troels Holz Borch, Morten Nielsen, Sofie Kirial Mørk, Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Lise Pyndt Jørgensen, Lene Buhl Riis, Christina Westmose Yde, Özcan Met, Marco Donia, Inge Marie Svane
Original research: Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity (1 October, 2021)
Congcong Zhang, Jasmin Röder, Anne Scherer, Malena Bodden, Jordi Pfeifer Serrahima, Anita Bhatti, Anja Waldmann, Nina Müller, Pranav Oberoi, Winfried S Wels

Oncolytic and local immunotherapy

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma (21 October, 2021)
Victoria M Leb-Reichl, Melanie Kienzl, Anna Kaufmann, Angelika Stoecklinger, Birgit Tockner, Sophie Kitzmueller, Nadja Zaborsky, Markus Steiner, Gabriele Brachtl, Lisa Trattner, Patrick Kreideweiss, Christian Reinsch, Steffen Panzner, Richard Greil, Dirk Strunk, Johann W Bauer, Iris K Gratz, Christina Guttmann-Gruber, Josefina Piñón Hofbauer
Original research: Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments (1 October, 2021)
Maulasri Bhatta, Gautam N Shenoy, Jenni L Loyall, Brian D Gray, Meghana Bapardekar, Alexis Conway, Hans Minderman, Raymond J Kelleher Jr, Beatriz M Carreno, Gerald Linette, Leonard D Shultz, Kunle Odunsi, Sathy V Balu-Iyer, Koon Yan Pak, Richard B Bankert
Original research: Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy (1 October, 2021)
Mohammed G Ghonime, Uksha Saini, Michael C Kelly, Justin C Roth, Pin-Yi Wang, Chun-Yu Chen, Katherine Miller, Ilse Hernandez-Aguirre, Yeaseul Kim, Xiaokui Mo, Joseph R Stanek, Tim Cripe, Elaine Mardis, Kevin A Cassady

Review

Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward (19 October, 2021)
Maria Rain Jennings, David Munn, John Blazeck
Immunological configuration of ovarian carcinoma: features and impact on disease outcome (13 October, 2021)
Jitka Fucikova, An Coosemans, Sandra Orsulic, David Cibula, Ignace Vergote, Lorenzo Galluzzi, Radek Spisek
Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment (12 October, 2021)
Feiya Ma, Jensen Vayalil, Grace Lee, Yuqi Wang, Guangyong Peng
Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis (1 October, 2021)
Alice Tzeng, Tony H Tzeng, Moshe C Ornstein

Main menu

Table of contents

October 2021 - Volume 9 - 10

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

October 2021 - Volume 9 - 10

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review

Correction